Endothelin Gene Polymorphisms Predict Beta-Blocker Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, particularly heart failure and cardiomyopathy, exhibit significant interindividual variability in response to β-blocker therapy, making it challenging to predict which patients will benefit from β-adrenergic receptor targeting agents, leading to suboptimal treatment outcomes.
Innovation Solution
Identifying specific polymorphisms in the endothelin gene system members, such as EDN1 SNPs at nucleotide positions +356 in intron 4 (rs2071942) and +61 in exon 5 (rs5370), to predict the efficacy of β-adrenergic receptor targeting agents like bucindolol, allowing for personalized treatment decisions based on a patient's genotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If β-blocker therapy is administered to treat heart failure, then mortality is reduced by 34-65%, but substantial interindividual variability in response occurs that is not explained by baseline clinical characteristics
Solution Approach 1:
The patent applies parameter changes by utilizing genetic polymorphism data (specific SNPs in endothelin gene system members) to identify and stratify patient subpopulations. This transforms the treatment approach from a uniform protocol to a personalized one based on genetic parameters, thereby resolving the contradiction between overall treatment efficacy and interindividual variability.
2Reliability
If β-blocker therapy is used as standard treatment for systolic heart failure, then all-cause mortality is reduced, but only 25-60% of patients benefit from exposure to medication as compared to placebo
Solution Approach 1:
The patent segments the heart failure patient population into distinct subgroups based on their genetic profile (presence or absence of specific endothelin gene polymorphisms). This segmentation allows identification of the 40-75% of patients who are likely to respond favorably to β-blocker therapy, thereby increasing the effective productivity or benefit rate of the treatment.
Solution Approach 2:
The patent implements preliminary action by performing genetic testing for endothelin gene polymorphisms before initiating β-blocker therapy. This pre-screening allows clinicians to predict which patients are likely to benefit from treatment, enabling informed decision-making about treatment initiation and avoiding exposure to ineffective therapy for non-responders.
3Measurement precision
If genetic testing for endothelin gene polymorphisms is performed to predict β-blocker efficacy, then personalized treatment decisions can be made, but additional testing time and resources are required
Solution Approach 1:
The patent employs disposable, standardized genetic testing assays for detecting endothelin gene polymorphisms. These testing methods are designed to be cost-effective and rapidly executable, minimizing the time and resource investment required while providing precise prediction of β-blocker treatment efficacy. The use of established SNP detection technologies ensures the testing is both accurate and efficient.
Data Source
AI summary
The present invention concerns the use of methods for evaluating β-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a β-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a β-blocker. Accordingly, methods of treatment are also described.